Casdin Capital LLC Makes New $11.62 Million Investment in DexCom, Inc. $DXCM

Casdin Capital LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, Holdings Channel reports. The firm bought 175,000 shares of the medical device company’s stock, valued at approximately $11,615,000. DexCom makes up 0.7% of Casdin Capital LLC’s investment portfolio, making the stock its 22nd biggest holding.

Other hedge funds have also made changes to their positions in the company. CVA Family Office LLC lifted its holdings in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the period. MCF Advisors LLC bought a new position in shares of DexCom in the 4th quarter worth $32,000. ORG Partners LLC raised its position in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. DV Equities LLC bought a new position in shares of DexCom in the 4th quarter worth $36,000. Finally, Spire Wealth Management raised its position in shares of DexCom by 113.8% in the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after acquiring an additional 305 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Canaccord Genuity Group set a $82.00 price target on DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Stifel Nicolaus set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, June 5th. BTIG Research reissued a “buy” rating and issued a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $91.00 price target on shares of DexCom in a research report on Monday, June 8th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.83.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 46,694 shares of company stock valued at $3,343,977. 0.28% of the stock is owned by insiders.

DexCom Trading Down 2.6%

Shares of NASDAQ:DXCM opened at $71.23 on Thursday. The business’s 50-day moving average is $66.75 and its 200 day moving average is $67.82. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a market capitalization of $27.49 billion, a P/E ratio of 30.44, a P/E/G ratio of 1.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 EPS. On average, research analysts predict that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.